FindTrial
Sign In

Etude de phase II évaluant l’association de cetuximab à une radiothérapie et chimiothérapie concomitante par cisplatine et pemetrexed dans le traitement des cancers bronchiques non à petites cellules non-épidermoïdes de stade III, inopérables

Etude de phase II évaluant l’association de cetuximab à une radiothérapie et chimiothérapie concomitante par cisplatine et pemetrexed dans le traitement des cancers bronchiques non à petites cellules non-épidermoïdes de stade III, inopérables

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2009-012412-41-FR
Enrollment
Unknown
Registered
2009-11-13
Start date
2010-01-11
Completion date
Unknown
Last updated
2016-07-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stage III Non-small cell lung cancer MedDRA version: 12.0 Level: LLT Classification code 10025052 Term: Lung cancer non-small cell stage III

Interventions

Trade Name: ERBITUX Product Name: Cetuximab Product Code: EMD271786 Pharmaceutical Form: Solution for injection Trade Name: ALIMTA Product Name: pemetrexed Product Code: LY231514 Pharmaceutical Form:

Sponsors

IFCT
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - [1] patient with NSCLC with non-squamous predominant histology - [2] patient with stage III NSCLC (classification TNM 2009) non-resectable, non-irradiable, - [3] One mesurable lesion(RECIST 1.1), - [12] age = 18 and =65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: Efficacy (Disease control rate after 16 weeks);Secondary Objective: Tolerance Progression-free Survival Overall Suvival;Primary end point(s): Disease Control Rate (at 16th week)—

Countries

France

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026